Basal-like breast carcinoma
MONDO:0004984A biologic subset of breast carcinoma defined by high expression of genes characteristic of basal epithelial cells, including KRT5 and KRT17, annexin 8, CX3CL1, and TRIM29, and usually by lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It is the most common subtype of breast cancer associated with BRCA1 mutations, and is associated with a poor prognosis.
Also known as: basal-like breast cancer, basal-like breast carcinoma, basal-like subtype of breast carcinoma
2803 clinical trials for this condition and its sub-types, 5 tagged with Basal-like breast carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for tough breast cancer: which chemo works best after surgery?
Disease control OngoingThis study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that remains after initial chemotherapy and surgery. About 415 participants with stage II-III breast cance…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Promising breast cancer drug trial pulled before starting
Disease control CancelledThis study aimed to see if the drug trastuzumab deruxtecan worked better than standard CDK4/6 inhibitors for people with a specific advanced breast cancer (ER-positive, HER2-low, non-luminal A). It was designed for adults with metastatic disease. However, the trial was withdrawn …
Phase 3 • Sponsor: Danish Breast Cancer Cooperative Group • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC